

RealRate

PHARMACEUTICAL 2020











RealRate

PHARMACEUTICAL 2020

Korro Bio Inc. Rank 69 of 358



The relative strengths and weaknesses of Korro Bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Korro Bio Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Korro Bio Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 157% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	221,355
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	52,780
Liabilities, Non-Current	3,080
Other Assets	101
Other Compr. Net Income	54
Other Expenses	16,000
Other Liabilities	0
Other Net Income	1,929
Other Revenues	28,947
Property and Equipment	1,762
Research and Development	18,784
Selling, General and Administrative Expense	14,838

Output Variable	Value in 1000 USD
Assets	223,218
Liabilities	55,860
Expenses	49,622
Revenues	28,947
Stockholders Equity	167,358
Net Income	-18,746
Comprehensive Net Income	-18,719
Economic Capital Ratio	193%

